Clinical Trials | July 27, 2022
Nuance Pharma announces the completion of dosing for all NTM-001 Phase 1 clinical study
The NTM-001 Phase I clinical study is expected to be completed by the end of 2022
The NTM-001 Phase I clinical study is expected to be completed by the end of 2022
The FDA informed Astellas that it did not have sufficient information to assess the risks to subjects
A separate global Phase 3 study of S-217622 is underway aiming to recruit participants globally to support regulatory filings this year
Approval for primary and booster immunization is based on efficacy and safety data from Japan and international clinical studies
At the interim analysis, the combination of Keytruda and Lynparza did not demonstrate a benefit in overall survival (OS), one of the study’s dual primary endpoints, compared to the control arm of either abiraterone acetate or enzalutamide
Sputnik Light can become a major booster for those vaccinated with inactivated Chinese Covid-19 vaccines globally after China has officially recommended mix & match approach with adenoviral vector-based vaccines as boosters
Monitoring results demonstrated a good safety profile of the combination. No serious adverse events related to vaccination were registered
Glenmark received manufacturing and marketing approval from DCGI for Nitric Oxide Nasal Spray (NONS) as part of accelerated approval process
This is the ninth Covid-19 vaccine approved in India
Highest safety and efficacy of Sputnik V confirmed during clinical trials and in real-world use in more than 60 countries around the world
Subscribe To Our Newsletter & Stay Updated
